Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDRX NASDAQ:CAPS NASDAQ:CELZ NASDAQ:SCNI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDRXBiodexa Pharmaceuticals$1.65-1.8%$2.84$1.64▼$59.40$3.29M1.2412,269 shs63,546 shsCAPSCapstone Therapeutics$0.23-5.9%$0.29$0.23▼$2.07$3.50M-1.51310,143 shs87,520 shsCELZCreative Medical Technology$0.81-0.1%$1.69$0.78▼$6.25$3.84M1.8910.14 million shs97,253 shsSCNIScinai Immunotherapeutics$0.23-6.9%$0.34$0.21▼$3.48$910K2.11541,542 shs35,206 shsThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDRXBiodexa Pharmaceuticals0.00%-22.54%-34.00%-50.00%-96.26%CAPSCapstone Therapeutics0.00%-10.39%-2.00%-45.62%-86.29%CELZCreative Medical Technology0.00%-7.85%-59.50%-64.78%-70.76%SCNIScinai Immunotherapeutics0.00%-7.93%-9.80%-68.79%-89.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDRXBiodexa Pharmaceuticals$1.65-1.8%$2.84$1.64▼$59.40$3.29M1.2412,269 shs63,546 shsCAPSCapstone Therapeutics$0.23-5.9%$0.29$0.23▼$2.07$3.50M-1.51310,143 shs87,520 shsCELZCreative Medical Technology$0.81-0.1%$1.69$0.78▼$6.25$3.84M1.8910.14 million shs97,253 shsSCNIScinai Immunotherapeutics$0.23-6.9%$0.34$0.21▼$3.48$910K2.11541,542 shs35,206 shsThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDRXBiodexa Pharmaceuticals0.00%-22.54%-34.00%-50.00%-96.26%CAPSCapstone Therapeutics0.00%-10.39%-2.00%-45.62%-86.29%CELZCreative Medical Technology0.00%-7.85%-59.50%-64.78%-70.76%SCNIScinai Immunotherapeutics0.00%-7.93%-9.80%-68.79%-89.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDRXBiodexa Pharmaceuticals 1.00SellN/AN/ACAPSCapstone Therapeutics 1.00SellN/AN/ACELZCreative Medical Technology 1.50ReduceN/AN/ASCNIScinai Immunotherapeutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest SCNI, CELZ, CAPS, and BDRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/20/2026CAPSCapstone Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)7/17/2026SCNIScinai Immunotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/2/2026CAPSCapstone Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)6/18/2026BDRXBiodexa Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)6/17/2026CAPSCapstone Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)6/3/2026BDRXBiodexa Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)6/3/2026CAPSCapstone Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/22/2026CELZCreative Medical Technology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/20/2026CAPSCapstone Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/13/2026BDRXBiodexa Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/6/2026CAPSCapstone Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDRXBiodexa Pharmaceuticals$470K7.02N/AN/A$110.30 per share0.01CAPSCapstone Therapeutics$48.11M0.07N/AN/A$1.37 per share0.17CELZCreative Medical Technology$10K383.94N/AN/A$2.04 per share0.40SCNIScinai Immunotherapeutics$1.31M0.70N/AN/A$0.78 per share0.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDRXBiodexa Pharmaceuticals-$8.42MN/AN/AN/AN/AN/AN/AN/A9/11/2026 (Estimated)CAPSCapstone Therapeutics-$21.23M-$3.37N/AN/AN/A-41.26%-114.15%-39.74%8/13/2026 (Estimated)CELZCreative Medical Technology-$5.99M-$2.14N/AN/AN/AN/A-88.38%-84.71%8/14/2026 (Estimated)SCNIScinai Immunotherapeutics-$8.31M-$1.06N/AN/AN/AN/AN/AN/A8/20/2026 (Estimated)Latest SCNI, CELZ, CAPS, and BDRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2026N/ACELZCreative Medical Technology-$0.39N/AN/AN/AN/AN/A8/13/2026Q2 2026CAPSCapstone Therapeutics$0.12N/AN/AN/A$20.39 millionN/A5/20/2026Q1 2026CAPSCapstone Therapeutics-$0.19-$0.21-$0.02-$0.21$10.80 million$12.64 million5/8/2026Q1 2026CELZCreative Medical Technology-$0.39-$0.38+$0.01-$0.38N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBDRXBiodexa PharmaceuticalsN/AN/AN/AN/AN/ACAPSCapstone TherapeuticsN/AN/AN/AN/AN/ACELZCreative Medical TechnologyN/AN/AN/AN/AN/ASCNIScinai ImmunotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDRXBiodexa PharmaceuticalsN/A2.032.03CAPSCapstone Therapeutics0.790.950.29CELZCreative Medical TechnologyN/A19.6719.67SCNIScinai Immunotherapeutics0.051.351.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDRXBiodexa Pharmaceuticals17.51%CAPSCapstone Therapeutics2.55%CELZCreative Medical Technology1.42%SCNIScinai Immunotherapeutics58.41%Insider OwnershipCompanyInsider OwnershipBDRXBiodexa Pharmaceuticals0.34%CAPSCapstone Therapeutics39.29%CELZCreative Medical Technology1.00%SCNIScinai Immunotherapeutics60.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDRXBiodexa Pharmaceuticals202.00 million1.99 millionNot OptionableCAPSCapstone Therapeutics3815.20 million9.23 millionN/ACELZCreative Medical Technology54.74 million4.69 millionNot OptionableSCNIScinai Immunotherapeutics203.96 million1.55 millionNot OptionableSCNI, CELZ, CAPS, and BDRX HeadlinesRecent News About These CompaniesScinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth InitiativesJune 10, 2026 | prnewswire.comScinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO FacilityMay 20, 2026 | prnewswire.comScinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit EuropeMay 15, 2026 | prnewswire.comScinai Immunotherapeutics Announces $2.61 Million Private Placement FinancingApril 24, 2026 | prnewswire.comScinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 PrioritiesApril 6, 2026 | prnewswire.comScinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm CollaborationApril 1, 2026 | prnewswire.comScinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026March 19, 2026 | prnewswire.comScinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid PriceMarch 16, 2026 | prnewswire.comScinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of ConceptMarch 2, 2026 | prnewswire.comScinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish PlatformFebruary 25, 2026 | prnewswire.comScinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with RecipharmFebruary 17, 2026 | prnewswire.comScinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthILJanuary 7, 2026 | prnewswire.comScinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Sees Large Drop in Short InterestJanuary 2, 2026 | defenseworld.netDScinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline AdvancesDecember 2, 2025 | prnewswire.comScinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO CapabilitiesOctober 6, 2025 | prnewswire.comScinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance SheetSeptember 2, 2025 | prnewswire.comScinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TENJuly 29, 2025 | prnewswire.comScinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025June 12, 2025 | prnewswire.comScinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.June 5, 2025 | prnewswire.comScinai Immunotherapeutics Reports Strong CDMO GrowthJune 2, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026Fiserv’s Debit Network Talks Raise a Bigger Question for Visa and MastercardBy Jeffrey Neal Johnson | July 9, 2026MarketBeat Week in Review – 07/06 - 07/10By MarketBeat Staff | July 11, 2026Small Caps Are Crushing the S&P 500—3 Stocks Still Worth BuyingBy Chris Markoch | July 22, 2026SCNI, CELZ, CAPS, and BDRX Company DescriptionsBiodexa Pharmaceuticals NASDAQ:BDRX$1.65 -0.03 (-1.79%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.68 +0.03 (+1.52%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Capstone Therapeutics NASDAQ:CAPS$0.23 -0.01 (-5.88%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$0.23 +0.00 (+0.26%) As of 07/24/2026 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.Creative Medical Technology NASDAQ:CELZ$0.81 0.00 (-0.06%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$0.79 -0.02 (-1.98%) As of 07/24/2026 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.Scinai Immunotherapeutics NASDAQ:SCNI$0.23 -0.02 (-6.92%) Closing price 07/24/2026 03:59 PM EasternExtended Trading$0.24 +0.00 (+2.17%) As of 07/24/2026 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
